Prolonged	prolonged	O	O	O	O
elevation	elevation	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
argatroban	argatroban	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
cardiac	cardiac	O	O	O	O
transplant	transplant	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
suspected	suspected	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
with	with	O	O	O	O
thrombosis	thrombosis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Direct	direct	O	O	OTHERS	I
thrombin	thrombin	O	O	OTHERS	I
inhibitors	inhibitors	O	O	OTHERS	I
(	(	O	O	O	O
DTIs	dtis	O	O	O	O
)	)	O	O	O	O
provide	provide	O	O	O	O
an	an	O	O	O	O
alternative	alternative	O	O	O	O
method	method	O	O	O	O
of	of	O	O	O	O
anticoagulation	anticoagulation	O	O	O	O
for	for	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
HIT	hit	O	DISEASE	OTHERS	I
)	)	O	O	O	O
or	or	O	O	O	O
HIT	hit	O	DISEASE	OTHERS	I
with	with	O	O	O	O
thrombosis	thrombosis	O	DISEASE	OTHERS	I
(	(	O	O	O	O
HITT	hitt	O	DISEASE	OTHERS	I
)	)	O	O	O	O
undergoing	undergoing	O	O	O	O
cardiopulmonary	cardiopulmonary	O	O	O	O
bypass	bypass	O	O	O	O
(	(	O	O	O	O
CPB	cpb	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
following	following	O	O	O	O
report	report	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
65-year-old	65-year-old	O	O	O	O
critically	critically	O	O	OTHERS	I
ill	ill	O	O	OTHERS	I
patient	patient	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
suspected	suspected	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
HITT	hitt	O	DISEASE	OTHERS	I
was	was	O	O	O	O
administered	administered	O	O	O	O
argatroban	argatroban	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
anticoagulation	anticoagulation	O	O	O	O
on	on	O	O	O	O
bypass	bypass	O	O	O	O
during	during	O	O	O	O
heart	heart	O	O	O	O
transplantation	transplantation	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
required	required	O	O	O	O
massive	massive	O	O	O	O
transfusion	transfusion	O	O	O	O
support	support	O	O	O	O
(	(	O	O	O	O
55	55	O	O	O	O
units	units	O	O	O	O
of	of	O	O	O	O
red	red	O	O	O	O
blood	blood	O	O	O	O
cells	cells	O	O	O	O
,	,	O	O	O	O
42	42	O	O	O	O
units	units	O	O	O	O
of	of	O	O	O	O
fresh-frozen	fresh-frozen	O	O	O	O
plasma	plasma	O	O	O	O
,	,	O	O	O	O
40	40	O	O	O	O
units	units	O	O	O	O
of	of	O	O	O	O
cryoprecipitate	cryoprecipitate	O	O	O	O
,	,	O	O	O	O
40	40	O	O	O	O
units	units	O	O	O	O
of	of	O	O	O	O
platelets	platelets	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
three	three	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
recombinant	recombinant	CHEMICALS	O	OTHERS	I
Factor	factor	CHEMICALS	O	OTHERS	I
VIIa	viia	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
for	for	O	O	O	O
severe	severe	O	O	O	O
intraoperative	intraoperative	O	O	O	O
and	and	O	O	O	O
postoperative	postoperative	O	O	O	O
bleeding	bleeding	O	DISEASE	OTHERS	I
.	.	O	O	O	O

STUDY	study	O	O	O	O
DESIGN	design	O	O	O	O
AND	and	O	O	O	O
METHODS	methods	O	O	O	O
:	:	O	O	O	O
Plasma	plasma	O	O	O	O
samples	samples	O	O	O	O
from	from	O	O	O	O
before	before	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
CPB	cpb	O	O	O	O
were	were	O	O	O	O
analyzed	analyzed	O	O	O	O
postoperatively	postoperatively	O	O	O	O
for	for	O	O	O	O
argatroban	argatroban	CHEMICALS	O	OTHERS	I
concentration	concentration	O	O	O	O
using	using	O	O	O	O
a	a	O	O	O	O
modified	modified	O	O	O	O
ecarin	ecarin	O	O	O	O
clotting	clotting	O	O	O	O
time	time	O	O	O	O
(	(	O	O	O	O
ECT	ect	O	O	O	O
)	)	O	O	O	O
assay	assay	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Unexpectedly	unexpectedly	O	O	O	O
high	high	O	O	O	O
concentrations	concentrations	O	O	O	O
of	of	O	O	O	O
argatroban	argatroban	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
measured	measured	O	O	O	O
in	in	O	O	O	O
these	these	O	O	O	O
samples	samples	O	O	O	O
(	(	O	O	O	O
range	range	O	O	O	O
,	,	O	O	O	O
0	0	O	O	O	O
-	-	O	O	O	O
32	32	O	O	O	O
microg/mL	microg/ml	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
prolonged	prolonged	O	O	O	O
plasma	plasma	O	O	O	O
argatroban	argatroban	CHEMICALS	O	OTHERS	I
half	half	O	O	O	O
life	life	O	O	O	O
(	(	O	O	O	O
t(1/2	t(1/2	O	O	O	O
)	)	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
514	514	O	O	O	O
minutes	minutes	O	O	O	O
was	was	O	O	O	O
observed	observed	O	O	O	O
(	(	O	O	O	O
published	published	O	O	O	O
elimination	elimination	O	O	O	O
t(1/2	t(1/2	O	O	O	O
)	)	O	O	O	O
is	is	O	O	O	O
39	39	O	O	O	O
-	-	O	O	O	O
51	51	O	O	O	O
minutes	minutes	O	O	O	O
[	[	O	O	O	O
<	<	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
181	181	O	O	O	O
minutes	minutes	O	O	O	O
with	with	O	O	O	O
hepatic	hepatic	O	O	OTHERS	I
impairment	impairment	O	O	OTHERS	I
]	]	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Correlation	correlation	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
argatroban	argatroban	CHEMICALS	O	OTHERS	I
concentration	concentration	O	O	O	O
versus	versus	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
coagulation	coagulation	O	O	O	O
variables	variables	O	O	O	O
and	and	O	O	O	O
clinical	clinical	O	O	O	O
course	course	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
prolonged	prolonged	O	O	O	O
elevated	elevated	O	O	O	O
levels	levels	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
argatroban	argatroban	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
have	have	O	O	O	O
contributed	contributed	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
extended	extended	O	O	O	O
coagulopathy	coagulopathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Because	because	O	O	O	O
DTIs	dtis	O	O	O	O
do	do	O	O	O	O
not	not	O	O	O	O
have	have	O	O	O	O
reversal	reversal	O	O	O	O
agents	agents	O	O	O	O
,	,	O	O	O	O
surgical	surgical	O	O	O	O
teams	teams	O	O	O	O
and	and	O	O	O	O
transfusion	transfusion	O	O	O	O
services	services	O	O	O	O
should	should	O	O	O	O
remain	remain	O	O	O	O
aware	aware	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
possibility	possibility	O	O	O	O
of	of	O	O	O	O
massive	massive	O	O	O	O
transfusion	transfusion	O	O	O	O
events	events	O	O	O	O
during	during	O	O	O	O
anticoagulation	anticoagulation	O	O	O	O
with	with	O	O	O	O
these	these	O	O	O	O
agents	agents	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
is	is	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
report	report	O	O	O	O
to	to	O	O	O	O
measure	measure	O	O	O	O
plasma	plasma	O	O	O	O
argatroban	argatroban	CHEMICALS	O	OTHERS	I
concentration	concentration	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
context	context	O	O	O	O
of	of	O	O	O	O
CPB	cpb	O	O	O	O
and	and	O	O	O	O
extended	extended	O	O	O	O
coagulopathy	coagulopathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

